Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Trade Show

Ayala Pharmaceuticals Announces Presentation at the European Society for Medical Oncology (ESMO)

Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers, today announced that a poster will be presented at the European Society for Medical Oncology (ESMO), being held in Barcelona, Spain from September 27 to October 1, 2019.

Presentation information is as follows:

Title: ACCURACY a phase (P) 2 trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) patients (pts) with Notch activating mutations (Notchact mut): preliminary safety and efficacy data 
Session Title: Poster Display Session 
Session Date and Time: Monday, September 30, 2019 at 12:00pm to 1:00pm CET 
Presentation Number: 1148P 
Location: Poster Area (Hall 4) 
Presenter: Alan L. Ho, M.D., Ph.D., Memorial Sloan Kettering Cancer Center

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. Ayala is broadly developing its product candidates, AL101 and AL102, best-in-class gamma secretase inhibitors, with clinical and preclinical studies underway in both solid tumors (AL101) and hematologic malignancies (AL102). Ayala's lead product candidate, AL101, is currently in phase 2 for adenoid cystic carcinoma patients with tumor bearing Notch activating mutations (ACCURACY). For more information, visit www.ayalapharma.com

These press releases may also interest you

at 02:41
If you use a cheap Hong Kong VPS hosting for your business purpose, you don't need to share the resources with others. This will surely improve the reliability, speed and security. In addition, you will get the full root control over your website so...

at 02:35
FSD Pharma Inc. (FRA: 0K9A) ("FSD Pharma" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has given the company permission to submit an Investigational New Drug Application (IND) for the use of FSD-201...

at 02:30
Key Highlights TGA has granted provisional designation for new drug Lurbinectedin based on encouraging Phase 2 results and high unmet medical need A marketing application has now been accepted by the TGA under provisional evaluation pathway...

at 02:15
Splunk Inc. today announced the pricing of $1.1 billion principal amount of 1.125% Convertible Senior Notes due 2027 (the "notes") in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as...

at 01:05
Onfido, Deloitte and Evernym today announced the positive results of their Financial Conduct Authority (FCA) regulatory sandbox pilot, confirming that their reusable digital identity solution has been proven with market participants. Testing began in...

at 01:00
Adapty Inc., a leading digital commerce and customer experience company, today announced the successful roll-out of a B2B e-commerce solution for Carotek, USA. Adapty partnered with Insite, an Episerver company, and Digital DNA Marketing agency to...

News published on 19 september 2019 at 16:05 and distributed by: